Plasma Cell Myeloma

Oncology·MeSH: Multiple Myeloma

36 drugs in development·5 companies·11 clinical trials

Drug Pipeline by Phase

Phase 3(14)

Drug	Company
belumosudil	Sanofi (SNY)
Bortezomib	Sanofi (SNY)
carfilzomib	Sanofi (SNY)
daratumumab	GH Research PLC (GHRS)
diphenhydramine or equivalent	Sanofi (SNY)
elotuzumab	GH Research PLC (GHRS)
Isatuximab	Sanofi (SNY)
isatuximab iv	Sanofi (SNY)
isatuximab sc	Sanofi (SNY)
montelukast	Sanofi (SNY)
Montelukast	Sanofi (SNY)
montelukast or equivalent	Sanofi (SNY)
Tocilizumab	ENANTA PHARMACEUTICALS INC (ENTA)
Venetoclax	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 2(4)

Phase 1(5)

Phase 1/Phase 2(11)

Phase 4(2)

Drug	Company
Belumosudil	Sanofi (SNY)
Belumosudil mesylate	Sanofi (SNY)

BioSniper tracks 36 drugs in development for Plasma Cell Myeloma across 5 companies.

There are 11 clinical trials targeting Plasma Cell Myeloma tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.